Document is current
Any future updates will be listed below
-
Authors
Knorr, Karina https://orcid.org/0000-0003-2022-4805
Oh, So Won
Krönke, Markus
Wurzer, Alexander
D’Alessandria, Calogero
Herz, Michael
Weber, Wolfgang
Wester, Hans-Jürgen
Eiber, Matthias
Yusufi, Nahid
Nekolla, Stephan
-
Funding
Funding for this research was provided by:
blue earth diagnostics
Technische Universität München
- License Information
-
More Information
Article History
Received: 2 July 2021
Accepted: 6 December 2021
First Online: 4 February 2022
Declarations
:
: The preclinical evaluation study was performed in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval #55.2-1-54-2532-216-2015). The retrospective analysis was approved by the Local Ethics Committee (permits 290/18S and 99/19S).
: Patient consent was waived by the local Ethics Committee (permits 290/18S and 99/19S) given the retrospective nature of the analysis.
: Patient consent was waived by the local Ethics Committee (permits 290/18S and 99/19S) given the retrospective nature of the analysis.
: Patent application for rhPSMA (HJW, AW and ME). HJW and ME received funding from the SFB 824 (DFG Sonderforschungsbereich 824, Project B11) from the Deutsche Forschungsgemeinschaft, Bonn, Germany and Blue Earth Diagnostics Limited (licensee for rhPSMA) as part of an academic collaboration. HJW is founder, shareholder and advisor board member of Scintomics GmbH, Fuerstenfeldbruck, Germany. WW is a consultant for Blue Earth Diagnostics Limited. ME reports prior consulting activities for Blue Earth Diagnostics, Progenics Pharmaceuticals, Point Biopharma and Janssen Pharmaceuticals. No other potential conflicts of interest relevant to this article exist.
